03.04.2018 • News

Erez Israeli Joins Dr. Reddy’s as New Chief Operating Officer

On Apr. 2, 2018, Erez Israeli joined Indian pharmaceutical company Dr. Reddy’s as COO and global head of Generics & PSAI. Israeli, former president & CEO of Enzymotec, succeeded Abhijit Mukherjee, who retired on Mar. 31, 2018, after 15 years with the company. In his Israely, he will report to Dr. Reddy’s co-chairman & CEO, G.V. Prasad.

Before joining Enzymotec, Israeli worked for 23 years at Teva Pharmaceuticals where he has held several leadership position.

G.V. Prasad commented on the transition: “I would like to thank Abhijit for his valuable contribution to our company’s growth journey over the past fifteen years. I extend a warm welcome to Erez Israeli. Erez is an accomplished leader with a proven track record of achievement. His knowledge and experience from leading pharmaceutical businesses of scale will be valuable for our future growth.”

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.